patient view report 2020

by Pearlie Becker Published 3 years ago Updated 2 years ago 3 min read

PatientView | Patient Focused Research, Publishing

14 hours ago Patient group experiences of the Covid 2020 pandemic. Published: September 29th, 2020. Pharmaceutical companies are being impacted by the actions they take in the Covid arena. Such actions may, or may not, elevate the corporate reputation of some of the big companies perceived to be acting effectively to help the world overcome the pandemic. >> Go To The Portal

How long has PatientView been doing this for?

Across our 20 year history, PatientView has collated evidence-based feedback on all these important subjects. Today, our most high-profile product concerns the corporate reputation of the pharmaceutical industry (from the perspective of patient groups).

What is the PatientView research on patient group relations?

Again, the reults will compare the feedback from patient groups in different therapy areas and geographic regions. The research is meant to support not only patient organisations themselves but those who work alongside them – by identifying strengths and weakness. PatientView research on patient group relations builds on previous work.

What is PatientView benchmarking?

Conducted by PatientView to determine the strength and power of the patient movement, data for which are available for 2012, 2014 and 2018. The benchmarking process relies on a system of self-assessment.

From the patient perspective 2019-2020

From 1 st November 2019 to 26 th February 2020, PatientView asked patient groups around the world to comment on the reputation of the pharmaceutical industry and individual companies within it.

The survey was conducted in 20 languages

Companies included in the 2020 publications of the corporate reputation survey

AbbVie I Acorda Therapeutics I Allergan I Almirall I Amgen I Astellas Pharma I AstraZeneca I Bayer I Bial I Biogen I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Chiesi Farmaceutici I CSL Behring I Daiichi Sankyo I Eisai I Eli Lilly (Lilly) I Ferring I Gedeon Richter I Gilead/Kite Pharma I Grifols I Grünenthal I GSK I Ipsen I Janssen I LEO Pharma I Lundbeck I Menarini I Merck & Co (MSD outside of the US) I Merck KGaA/EMD Group I Novartis I Novo Nordisk I Octapharma I Otsuka I Pfizer I Pierre Fabre Laboratories I Roche (Genentech in the US, Chugai in Japan) I Sanofi I Servier I Takeda (including Shire) I Teva I UCB I Vertex Pharmaceuticals I Vifor I ViiV Healthcare.